SCHEMBL20178664

SCHEMBL20178664

COC(=O)c1ccc2c(c1)CCN(S)C2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 6/20 0.51
HDAC8 Q9BY41 3/20 0.51
ACACB O00763 1/20 0.50
NAMPT P43490 4/20 0.46
ESR1 P03372 1/20 0.45
ESR2 Q92731 1/20 0.45
LIPE Q05469 1/20 0.44
SRD5A1 P18405 1/20 0.44
SRD5A2 P31213 1/20 0.44
MAPK1 P28482 1/20 0.43
TP53 P04637 1/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA7 P43166 2/20 0.43
CA9 Q16790 2/20 0.43
CA14 Q9ULX7 2/20 0.43
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
CA12 O43570 1/20 0.42
XDH P47989 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12682930 0.84 HDAC6 (0.56) HDAC6HDAC8ACACBNAMPTESR1
SCHEMBL1027755 0.84 HDAC6 (0.56) HDAC6HDAC8ACACBNAMPTESR1
SCHEMBL31276014 0.84 HDAC6 (0.56) HDAC6HDAC8ACACBNAMPTESR1
SCHEMBL3307342 0.84 DRD1 (0.51) HDAC6HDAC8ACACBLIPESRD5A1
SCHEMBL7865877 0.82 ACACB (0.53) HDAC6HDAC8ACACBNAMPTESR1
SCHEMBL12608358 0.81 HDAC6 (0.50) HDAC6HDAC8ACACBSRD5A1SRD5A2
SCHEMBL20178682 0.81 ALDH1A1 (0.56) HDAC6HDAC8SRD5A1SRD5A2MAPK1
SCHEMBL1263724 0.81 HDAC6 (0.53) HDAC6HDAC8ACACBNAMPTESR1
SCHEMBL8283285 0.81 ESR2 (0.70) HDAC6HDAC8ACACBNAMPTESR1
SCHEMBL20178678 0.80 ACACB (0.48) HDAC6HDAC8ACACBNAMPTESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-03-24 US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF NR1H4, FXR1, SLC10A1 HDAC6 597/4885HDAC8 1166/4885ACACB 797/4885
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof NR1H4, FXR1, SLC10A1 HDAC6 597/4885HDAC8 1166/4885ACACB 797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.